Onxeo Sa Stock Current Valuation
| C4X Stock | 0.07 0.0008 1.16% |
Valuation analysis of Onxeo SA helps investors to measure Onxeo SA's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Onxeo SA's price fluctuation is out of control at this time. Calculation of the real value of Onxeo SA is based on 3 months time horizon. Increasing Onxeo SA's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Onxeo SA's intrinsic value may or may not be the same as its current market price of 0.07, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0682 | Real 0.0653 | Hype 0.07 |
The intrinsic value of Onxeo SA's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Onxeo SA's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Onxeo SA helps investors to forecast how Onxeo stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Onxeo SA more accurately as focusing exclusively on Onxeo SA's fundamentals will not take into account other important factors: Onxeo SA Company Current Valuation Analysis
Onxeo SA's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Onxeo SA Current Valuation | 5.01 M |
Most of Onxeo SA's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Onxeo SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Onxeo SA has a Current Valuation of 5.01 M. This is much higher than that of the sector and significantly higher than that of the Current Valuation industry. The current valuation for all Germany stocks is notably lower than that of the firm.
Onxeo Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Onxeo SA's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Onxeo SA could also be used in its relative valuation, which is a method of valuing Onxeo SA by comparing valuation metrics of similar companies.Onxeo SA is currently under evaluation in current valuation category among its peers.
Onxeo Fundamentals
| Current Valuation | 5.01 M | |||
| Price To Book | 0.46 X | |||
| Price To Sales | 4.31 X | |||
| Total Debt | 9.91 M | |||
| Market Capitalization | 46.31 M | |||
| Total Asset | 53.06 M | |||
| Z Score | 2.4 | |||
| Net Asset | 53.06 M |
About Onxeo SA Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Onxeo SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Onxeo SA using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Onxeo SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Onxeo Stock Analysis
When running Onxeo SA's price analysis, check to measure Onxeo SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Onxeo SA is operating at the current time. Most of Onxeo SA's value examination focuses on studying past and present price action to predict the probability of Onxeo SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Onxeo SA's price. Additionally, you may evaluate how the addition of Onxeo SA to your portfolios can decrease your overall portfolio volatility.